Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Revenue to profit Fiscal 2025, year to 31 December 2025

Of every $100 of revenue, $2848.63 was left as profit. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue0.0100.0%
Cost of revenue0.0−8.6%
Gross profit0.091.4%
Research & development0.0−365.2%
Selling, general & admin0.0−430.3%
Other operating costs0.0−8.6%
Operating income0.0−712.7%
Other income, net0.0−192.5%
Income tax0.01.4%
Other items+0.23752.4%
Net income0.22848.6%
Revenue, operating income and net income, ten yearsRevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$0.2B$0.1B$0.2B$0.3B$0.2B$0.2B$0.1B$0.0B$0.0B$0.0B
Operating income−$0.1B−$0.1B−$0.1B−$0.1B−$0.2B−$0.3B−$0.3B−$0.3B−$0.2B$0.0B
Net income−$0.1B−$0.1B−$0.1B−$0.1B−$0.2B−$0.3B−$0.3B−$0.3B$0.0B$0.2B
Net margin (right axis)−31.7%−92.3%−40.6%−30.0%−107.4%−123.3%−208.7%−607.3%−160.6%2848.6%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
6.44 29.62 46.80 140.73 235.31 176.32 256.58 212.96 131.00 183.19
Revenue Growth
(78.26%) (36.71%) (66.74%) (40.19%) 33.46% (31.28%) 20.48% 62.57% (28.49%) 1.31%
Gross Profit
5.88 14.06 42.84 120.45 222.44 167.45 255.43 212.96 131.00 183.19
Operating Income
(45.89) (150.42) (322.72) (301.02) (288.53) (191.88) (89.31) (86.69) (117.28) (50.04)
EBT
(58.29) (153.37) (323.22) (294.87) (290.68) (188.73) (76.64) (86.12) (120.55) (58.14)
Income after Tax
(58.20) (153.10) (322.97) (295.23) (291.03) (189.09) (76.97) (86.42) (120.87) (58.07)
Net Income Common
183.45 (47.58) (284.23) (293.65) (290.02) (189.29) (76.97) (86.42) (120.87) (58.07)
EPS (Diluted)
45.37 (12.00) (73.00) (78.50) (78.50) (52.75) (22.25) (25.75) (43.25) (24.50)
Shares (Diluted, Weighted)
4.04 4.00 3.89 3.74 3.69 3.59 3.47 3.36 2.92 2.51
Gross Margin
91.37% 47.47% 91.53% 85.59% 94.53% 94.97% 99.55% 100.00% 100.00% 100.00%
EBIT Margin
(712.66%) (507.80%) (689.53%) (213.90%) (122.62%) (108.83%) (34.81%) (40.71%) (89.53%) (27.32%)
Net Profit Margin
2,848.63% (160.63%) (607.29%) (208.66%) (123.25%) (107.36%) (30.00%) (40.58%) (92.27%) (31.70%)
Free Cash Flow Margin
(74.72%) (463.25%) (678.46%) (131.22%) (47.77%) 44.02% (32.92%) (39.44%) (57.26%) 3.20%
EBITDA
(45.22) (149.40) (317.85) (288.80) (271.24) (169.73) (71.53) (80.17) (109.34) (41.27)
EBIT
(45.89) (150.42) (322.72) (301.02) (288.53) (191.88) (89.31) (86.69) (117.28) (50.04)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026